我国诊疗一体化核素及放射性药物临床应用与展望

Development and Prospect of Theranostic Medical Isotopes and Radiopharmaceuticals in China

核医学诊疗一体化是将放射性核素显像与内放射治疗相结合,从而实现疾病的可视化诊断和精准治疗。目前,核医学诊疗一体化已在分化型甲状腺癌、嗜铬细胞瘤、恶性肿瘤骨转移、神经内分泌肿瘤、前列腺癌中发挥重要作用。我国医用放射性核素及放射性药物短缺,严重依赖进口,存在“卡脖子”问题,应加强诊疗一体化医用放射性核素及放射性药物的自主生产与创新研发力度,以促进核医学诊疗一体化更好地服务我国临床实践。

Theranostics in nuclear medicine is the combination of radionuclide imaging and internal radiotherapy, so as to realize the visualized diagnosis and precise treatment of diseases. At present, theranostics of nuclear medicine has played an important role in differentiated thyroid carcinoma, pheochromocytoma, bone metastases, neuroendocrine tumors and prostate cancer. China’s medical radionuclides and radionuclide medicines are in short supply and heavily dependent on imports, so there is a “bottleneck” problem. It is necessary to strengthen the independent production, innovation and research of medical radionuclides and radiopharmaceutics of theranostics, so as to promote theranostics of nuclear medicine to better serve China’s clinical practice.